MARKET

TBPH

TBPH

Theravance Bioph
NASDAQ
17.77
-0.40
-2.20%
After Hours: 17.77 0 0.00% 16:21 12/15 EST
OPEN
18.28
PREV CLOSE
18.17
HIGH
18.36
LOW
17.70
VOLUME
441.48K
TURNOVER
--
52 WEEK HIGH
20.33
52 WEEK LOW
7.90
MARKET CAP
900.45M
P/E (TTM)
31.59
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TBPH last week (1208-1212)?
Weekly Report · 20h ago
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?
NASDAQ · 5d ago
Theravance Biopharma’s Ampreloxetine: A Promising Candidate for Neurogenic Orthostatic Hypotension with Strong Market Potential
TipRanks · 5d ago
Theravance Biopharma’s Ampreloxetine: A Promising Solution for MSA with Strategic Market Positioning
TipRanks · 6d ago
Theravance Biopharma’s Ampreloxetine: A Promising Treatment for Neurogenic Orthostatic Hypotension with Strong Commercial Prospects
TipRanks · 6d ago
Theravance Biopharma Hosts Key Opinion Leader Event
TipRanks · 12/08 11:56
Weekly Report: what happened at TBPH last week (1201-1205)?
Weekly Report · 12/08 09:32
Theravance Biopharma SVP Rhonda Farnum Sells Common Shares
Reuters · 12/05 23:02
More
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Webull offers Theravance Biopharma Inc stock information, including NASDAQ: TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.